Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Tenosynovial giant cell tumour (TGCT), drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Duration of CSF1R therapy and rebound after stopping: extension cohorts and intermittent schedules are being studied.
Hepatotoxicity of pexidartinib: newer agents (vimseltinib, emactuzumab) are designed to avoid it.
Neoadjuvant use to make surgery smaller or unnecessary: phase 2 studies under way.
Access and cost for a benign disease in health systems that price by survival gain.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025
Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity
FDA approval 14 February 2025 for symptomatic TGCT where surgery would worsen function.
ORR 40% vs 0%.
Gelderblom and colleagues, Lancet.